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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not
narrowband ultraviolet B (NB-UVB) phototherapy is effective monotherapy in the treatment of
adults with plaque psoriasis.
STUDY DESIGN: Review of three English language primary randomized controlled studies
published in 2006 and 2009.
DATA SOURCES: Randomized, investigator-blind, active treatment-controlled trials comparing
NB-UVB phototherapy to other treatment options were found using MEDLINE, OVID, and
COCHRANE databases.
OUTCOME(S) MEASURED: Each of the three trials assessed improvement of the overall
psoriatic lesions by the investigator and the patient based on the presence and severity of
erythema, scaling, induration, itch, redness/irritation, burning sensation, height of lesion,
size/area, and roughness/texture. Investigators completed a Psoriasis Area Severity Index score,
Physician’s Global Assessment of Clearance, and rated severity of symptoms on a scale of 0
(none) to 4 (severe). Patients completed a Dermatology Quality of Life Index, Visual Analog
Scale from 0 (none) to 10 (worse ever experienced), and rated severity of symptoms on a scale of
0 (none) to 6 (severe).
RESULTS: Three randomized controlled trials were included in this review. Results from each
trial indicate that NB-UVB monotherapy can successfully treat plaque psoriasis in that it
provides relief of symptoms and clearance of the lesions. However, although NB-UVB was
effective, each of the comparison treatments demonstrated alleviation of symptoms and treatment
of lesions in a shorter period of time. In all three trials, erythema was found to be an adverse
reaction.
CONCLUSIONS: Each trial portrays that NB-UVB is effective monotherapy for the treatment of
plaque psoriasis. In spite of this, the efficiency of this treatment option is of question due to the
findings that the comparison treatment options showed a more prompt clearance of lesions.
KEY WORDS: Psoriasis; UVB; phototherapy
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INTRODUCTION
Psoriasis is a genetically inherited dermatologic condition that affects 1.5 to 2% of
the world’s western population, and it currently affects 7.5 million people in the United States.1,2
This diagnosis has multiple different presentations such as plaque psoriasis, guttate psoriasis,
pustular psoriasis, inverse psoriasis, amongst others. Eighty to ninety percent of psoriasis
patients have plaque-type psoriasis.1 Plaque psoriasis specifically can cause physical and
cosmetic problems for patients, which can in turn lead to a negative impact on the patient’s
quality of life. These patients typically present with erythematous raised patches of silvery skin
which are mainly found on the extensor surfaces of the body, and can lead to long term sequelae.
Unfortunately, at the current time, there is no cure for psoriasis. It is estimated that
$11.25 billion are spent annually for psoriasis patients, and it has been reported that more than
three million health care visits occur each year.2,3 The exact cause of psoriasis is unknown;
however, at this time it has been found that there is an autoimmune component which involves
an overstimulated T-cell response of the immune system, as well as increased cell turn over time
of the keratinocytes.1 Physician assistants working in primary care settings may be the first
healthcare provider to recognize and educate patients on the diagnosis of plaque-type psoriasis.
Gaining knowledge and being able to prescribe a patient with the best treatment options is an
important role for physician assistants as the condition can be uncomfortable both physically and
cosmetically for the patient.
There are multiple treatment options available for the condition. Common systemic
methods include narrowband ultraviolet B (NB-UVB) phototherapy, oral psoralen-ultraviolet-A
(PUVA) photochemotherapy such as 8-methoxypsoralen (8-MOP) and exposure to UVA, oral
retinoids such as aceitretin and isotretoin, oral methotrexate, oral cyclosporin, and monoclonal
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antibodies such as alefacept, efalizumab, infliximab, adalimmab, and etanercept.1 Adjunctive
therapy is also available for localized plaques including topical glucocorticoids, vitamin D
analogues, tararotene, and topical tacrolimus/pimecrolimus.1 The treatment options mentioned
above all play an effective role in treating psoriasis. However, as with all medications, each
option will have a different effect on each patient with different rates of efficacy and adverse
reactions. NB-UVB phototherapy has been shown to be effective in the treatment of generalized
plaque psoriasis, and will be discussed further in this review.
OBJECTIVE
The objective of this systematic review is to determine whether or not NB-UVB
phototherapy is effective monotherapy in the treatment of adults with plaque psoriasis.
METHODS
Each of the three studies selected were randomized controlled clinical trials and met the
following criteria. The population included patients who were greater than 18 years of age with
diagnosed chronic, stable, plaque psoriasis. The intervention used consisted of NB-UVB
phototherapy. This intervention was compared to a different treatment option in each of the
three different studies. These comparisons included 0.1% 8-MOP cream followed within 15
minutes by NB-UVB phototherapy, 15% liquor carbonis distillate (LCD) solution plus NB-UVB
phototherapy, and a 10 mg 8-MOP tablet two hours before receiving PUVA. Outcomes of each
of the treatment options were determined by the improvement of the overall psoriatic lesions
which were assessed by the investigator and the patient. These improvements were based on the
presence and severity of erythema, scaling, induration, itch, redness/irritation, burning sensation,
height of lesion, size/area, and roughness/texture.
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Key words used to locate literature were psoriasis, UVB, and phototherapy. All articles
were published in English, and published in peer- reviewed journals. Research for the articles
was performed by the author via MEDLINE, OVID, and COCHRANE databases. Articles were
selected based on relevance and that the outcomes of the studies mattered to patients (POEMs).
Inclusion criteria for consideration of the study was that it was a randomized controlled trial
published after 1996. Exclusion criteria included patients who were under the age of 18 years
old, had recent treatment for psoriasis, or photosensitivity disorders. Statistics were reported
using p-value, numbers needed to treat (NNT), relative benefit increase (RBI), and absolute
benefit increase (ABI).
OUTCOMES MEASURED
Each of the three trials assessed improvement of the overall psoriatic lesions. This
assessment was completed by both the investigator and the patient based on the presence and
severity of erythema, scaling, induration, itch, redness/irritation, burning sensation, height of
lesion, size/area, and roughness/texture of the lesions. Investigators completed a Psoriasis Area
Severity Index (PSI-95) score, the Physician’s Global Assessment of Clearance, and rated the
severity of symptoms on a scale of 0 (none) to 4 (severe). Patients completed a Dermatology
Quality of Life Index, Visual Analog Scale from 0 (none) to 10 (worse ever experienced), and
rated severity of symptoms on a scale of 0 (none) to 6 (severe). Digital photographs were also
taken throughout the studies to demonstrate the improvement of the lesions.
Bagel also asked patients to evaluate the comparison treatment option which was LCD.
Patients graded the product on a scale of 1 (poor) to 9 (excellent). Each parameter used to
determine the outcome of each study was patient-oriented evidence that matters to the patient
involved.
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Table 1. Demographics and characteristics of included studies.
Study

Type

#
Age
Pts (yrs)

Inclusion
Criteria

Exclusion Criteria W/D

Interventions

Amor- RCT
npinyokeit,
2006 (1)

12 18-61

Patients who
Patients who received 2
were 18 years or photo (chemo)
older with
therapy within the
stable, plaque- past 8 wks, topical
type psoriasis treatments within the
past 4 wks, are
pregnant, lactating,
have a
hypersensitivity to
psoralen, or have
photosensitivity
disorders

NB-UVB
phototherapy VS.
0.1% 8-MOP
cream, followed
within 15 minutes
by NB-UVB
phototherapy

Bagel, RCT
2009 (2)

13 25-67

Adults who
were in good
health apart
from the
diagnosis of
chronic
symmetrically
distributed
plaque psoriasis

Patients who were
1
receiving any other
treatments for
psoriasis, or who had
intolerance to coal tar
or ultraviolet
radiation.

NB-UVB
phototherapy VS.
100 mL of 15%
liquor carbonis
distillate (LCD)
solution applied
BID to psoriatic
lesions (except
face,scalp,groin)
plus NB-UVB
phototherapy

Yones, RCT
2006 (3)

93 18-70

Patients 18-70
years old with
chronic plaque
psoriasis with at
least 8% body
surface area
involvement
with a Psoriasis
Area and
Severity Index
(PASI) score of
at least 8

Patients with
5
previous skin
malignancy, recent
photo(chemo)therapy
or > 150 sessions in
lifetime, history of or
use of a drug causing
photosensitivity,
topical/systemic
antipsoriatic
treatment in the past
3 months pregnancy,
lactation, or
renal/hepatic disease

Placebo tablet 2
hours before
receiving NB-UVB
phototherapy VS.
10 mg 8methoxypsoralen
tablet 2 hours
before receiving
psoralenultraviolet-A
(PUVA)

4
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RESULTS
The results of each of the three trials evaluated were presented as dichotomous data in
order to evaluate the improvement of the lesions with NB-UVB monotherapy.
Amornpinyokeit et al found that of the ten patients involved in the study, three patients
achieved clearance of the psoriatic lesions with NB-UVB monotherapy. However, four of the
ten patients experienced clearance with 8-MOP/NB-UVB combination therapy. This data
demonstrates that there is a -25% RBI and a -10% ABI when comparing NB-UVB with
8-MOP/UVB combination therapy. NNT for this study was found to be -10 patients and the
p-value was 0.199 (Table 2). The negative value of NNT indicates that for every ten patients
who were given NB-UVB monotherapy, there would be one fewer patient who would achieve
PSI-95 than if they would have been treated with the combination therapy.
Yones et al compared the treatment of NB-UVB and 8-MOP/PUVA combination in a
study enrolled with eighty-eight patients. It was calculated that the RBI was -35% and the ABI
was -28%. The NNT was determined to the -4 patients and neither a p-value nor confidence
interval was given (Table 2). The negative value of NNT in this study indicates that for every
four patients who were given UVB monotherapy, there would be one fewer patient who would
have complete clearance than if they would have been treated with the combination
8-MOP/PUVA.
The study performed by Bagel determined the results of NB-UVB monotherapy versus
LCD/NB-UVB combination therapy. RBI and ABI were calculated to be -14.2% and -8.3%,
respectively. NNT was -13 patients and p-value was reported to be insignificant (Table 2). In
this trial, the negative value of NNT indicates that for every thirteen patients who were given
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UVB monotherapy, there would be one fewer patient who would have complete clearance than if
they would have been treated with the combination LCD/UVB therapy.
Table 2. Analysis of efficacy and safety in the evaluation of the clearance of psoriatic
lesions with NB-UVB monotherapy.
Study

Relative
benefit
increase (RBI)

Absolute
benefit increase
(ABI)

Number needed
to treat (NNT)

p-value

Amornpinyokeit,
2006

-25%

-10%

-10

0.199

Yones, 2006

-35%

-28%

-4

Not given

Bagel, 2009

-14.2%

-8.3%

-13

Insignificant

In addition to the overall evaluation of the clearance of the lesions, each of the clinical
trials determined the mean number of treatment sessions the patients underwent in order to
obtain PSI-95. Each of the three studies showed to have a reduced amount of sessions needed
for clearance when using the comparison treatment option. As can be seen in Table 3, patients
who received the 8-MOP/UVB treatment, the 8-MOP/PUVA combination therapy, or the
LCD/NB-UVB treatment achieved clearance in an average of 5 sessions, 11.5 sessions, and 9
sessions, respectively, less than when treated with NB-UVB monotherapy. Therefore, although
both lesions receiving treatment cleared with time regardless of the treatment option used, results
showed that “the side that received the combination cleared faster than the contralateral lesions
receiving the NB-UVB treatment...however, did not find that such combinations were superior to
NB-UVB alone.” 4
Furthermore, two of the three trials discussed the length of time until the patient
experienced relapse of their psoriatic lesions. This data is also presented in Table 3 and
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reinforces the lack of cure for plaque type psoriasis, as all patients relapsed with time regardless
of treatment. In the trial conducted by Amornpinyokeit et al, all patients had relapse of lesions
by twelve weeks with both the NB-UVB monotherapy and 8-MOP/NB-UVB combination
therapy. Similar results were found with the comparison of the NB-UVB monotherapy versus
the 8-MOP/PUVA combination. Yones et al reported “that patients treated with PUVA had
significantly longer remissions, with the median time to relapse being eight months versus four
months among patients being treated with NB-UVB.” 5
Table 3. Number of treatment session until clearance of lesions and length of time until
remission.
Treatment

Number of treatment
sessions until clearance

Length of time
until remission

NB-UVB monotherapy
vs. 8-MOP/NB-UVB

7.67 vs. 2.50

All patients relapsed by 12
weeks post-treatment

NB-UVB monotherapy
vs. 8-MOP/PUVA

28.5 vs 17.0

16 weeks vs. 32 weeks

NB-UVB monotherapy
vs. LCD/NB-UVB

21.0 vs 12.0

Not discussed

Lastly, adverse effects of the treatment options were discussed in each of the trials.
Among the three studies, no major complications were encountered. The most common
complication reported was erythema which was reported in each trial to a different degree. The
information is displayed below in Table 4. All ten patients enrolled in the Amornpinyokeit et al
study reported erythema with both treatment options. In the trial conducted by Yones et al, a
significantly less amount of erythema was reported by those who underwent the NB-UVB
therapy versus the 8-MOP/PUVA combination therapy with reported cases being 22% versus
49% respectively. The study that evaluated LCD/NB-UVB therapy was more specific in
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documenting the degree of erythema. Bagel stated that “adverse reactions consisted of one
report of mild and two reports of moderate post-UVB erythema, which appeared uniformly on
both sides of the body.” 6
Table 4. Adverse Effects: Erythema reported during trials
Treatment

Reported cases of erythema

Percentage

NB-UVB monotherapy
vs. 8-MOP/NB-UVB

10/10 vs. 10/10
of enrolled patients

100% vs. 100%

NB-UVB monotherapy
vs. 8-MOP/PUVA

10/45 vs. 21/43
of enrolled patients

22% vs 49%

NB-UVB monotherapy
vs. LCD/NB-UVB

3/12 vs 3/12
of enrolled patients

25% vs 25%

DISCUSSION
NB-UVB has been shown to be an effective treatment option for plaque-type psoriasis, as
demonstrated through each of the trails discussed above. This type of phototherapy is also
utilized to treat many other dermatological diagnoses. NB-UVB treatment is a readily accepted
and available treatment option in the United States. Despite this, healthcare professionals may
encounter problems with patient compliance due to the frequent and continuous need for
phototherapy sessions, as well as its cost. Common side effects encountered while using NBUVB are erythema, hyperpigmentation, photosensitivity, and worsening of the condition.
Erythema is the most prevalent adverse reaction, and was reported to some extent in each of the
clinical trials. This side effect may be avoided by beginning the treatment at a lower dosage.
Contraindications for the use of NB-UVB are photosensitivity disorders, chronic phototherapy
use in the past, pregnancy, lactation, and previous or current skin cancer.
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Although the data presented supports the use of NB-UVB, not all of the data presented in
this review is considered to be clinically significant as shown by the p-values in the studies by
Amornpinyokeit et al and Bagel et al. Also, study size in these trials puts a limit on the validity
of the results, with participants only adding up to a total of 110 patients for all three trials.
CONCLUSION
In conclusion, NB-UVB phototherapy is an effective monotherapy for the treatment of
adults with plaque psoriasis. However, other treatment options have been presented and have
also been shown be effective for clearance of lesions and alleviation of symptoms for psoriasis
patients. Therefore, an important conclusion can be made that NB-UVB phototherapy alone may
be a less efficient treatment option, but it is not a less superior treatment when compared to other
options available.
Future research for the use of NB-UVB phototherapy would be beneficial if the trial was
exclusively for patients with the same skin types in order to focus on the most effective dosage to
achieve resolution without sustaining adverse effects. Also, the future for the treatment of adults
with plaque-type psoriasis includes finding a cure; therefore, research that would lengthen
remission time and ultimately eliminate remission all together would provide the most benefit.
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